{
    "title": "SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant",
    "keywords": [
        "SARS-CoV-2",
        "COVID-19",
        "ORF3b",
        "type I interferon",
        "evolution 24 Abstract: 147/150 words"
    ],
    "author": "Kei Sato MB19",
    "date": 2020,
    "affiliations": [
        "Division of Systems Virology, Department of Infectious Disease Control",
        "International Research Center for Infectious Diseases, Institute of Medical Science, 9 the University of Tokyo, Tokyo 1088639, Japan 10",
        "Graduate School of Medicine, the University of Tokyo, Tokyo 1130033, Japan 11",
        "Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 12 7398511, Japan 13",
        "Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 6068507",
        "Department of Molecular Life Science, Tokai University School of Medicine",
        "Kanagawa 2591193, Japan 17",
        "These authors contributed equally. 19",
        "Correspondence:"
    ],
    "journal": "WHO",
    "identifiers": {
        "arxiv": null,
        "doi": "10.1101/2020.05.11.088179",
        "isbn": null,
        "doc_id": null,
        "url": "http://biorxiv.org/cgi/content/short/2020.05.11.088179.pdf"
    },
    "funding": [
        {
            "award-group": [
                {
                    "funding-source": "Kotubu Misawa for"
                },
                {
                    "funding-source": "AMED Research Program on Emerging and Re-emerging Infectious Diseases",
                    "award-id": [
                        "to K.S."
                    ]
                }
            ],
            "funding-statement": "We thank Kotubu Misawa for dedicated support. This study was supported in part by AMED Research Program on Emerging and Re-emerging Infectious Diseases 20fk0108146h0001 (to K.S.); AMED"
        }
    ]
}